
    
      The primary endpoint of safety and feasibility study will be done when the patient has
      received treatment at 12 months after implantation. It defines that the process is safe when
      in the development and monitoring of the trial there has been no adverse events that may be
      related to the proposed therapy in the trial. All adverse events will be collected during the
      same time monitoring the clinical evaluation. The main objective will be assessed the
      cumulative incidence of adverse effects attributed to the study therapy.

      Secondary endpoints: As part of the evaluation of the quality of life of patients and
      clinical evaluation of the treatment will be at 6, 9 and 12 months after implantation a Test
      SF-12, a magnetic resonance angiography, and tissue oximetry records ankle-brachial index
    
  